References
- United States Census Bureau [Internet]. Percent distribution of the projected population by selected age groups and sex for the United States: 2015-2060 [cited 2016 Jan 19]. http://www.census.gov/population/projections/data/national/2012/summarytables.html
- Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene. 2004;23:6524–6534.
- Smith SD, Chen A, Spurgeon S, et al. Diffuse large B-cell lymphoma in adults aged 75 years and older: a single institution analysis of cause-specific survival and prognostic factors. Ther Adv Hematol. 2013;4:349–353.
- Diffuse large B-cell lymphoma (DLBCL) [Internet]. Lymphoma Research Foundation website [cited 2016 Jun 20]. http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=6300153
- Union for International Cancer Control. Diffuse large B-cell lymphoma. Diffuse large B-cell lymphoma: 2014 Review of Cancer Medicines on the WHO List of Essential Medicines [Internet]. World Health Organization website [cited 2017 Jun 22]. http://www.who.int/selection_medicines/committees/expert/20/applications/DiffuseLargeBCellLymphoma.pdf
- Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
- Williams JN, Rai A, Lipscomb J, et al. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. Cancer. 2015;121:1800–1808.
- Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:498–505.
- Kutikova L, Bowman L, Chang S, et al. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. Leuk Lymphoma. 2006;47:1535–1544.
- Danese MD, Griffiths RI, Gleeson ML, et al. Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy. Leuk Lymphoma. 2017;58:1094–1104.
- Health Insurance Portability and Accountability Act of 1996. Public Law 104-191, 104th Congress, US Department of Health and Human Services [Internet] [cited 2016 Nov 18]. https://www.gpo.gov/fdsys/pkg/PLAW-104publ191/pdf/PLAW-104publ191.pdf. Published August 12, 1996.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN® Guidelines) for B-Cell Lymphomas V.3.2017. © National Comprehensive Cancer Network, Inc 2017. All rights reserved [cited 2017 Sep 5]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Shao C, Liu J, Zhou W, et al. Utilization patterns and resource use in relapse/refractory Hodgkin lymphoma (rrHL) patients treated with brentuximab vedotin (BV). Blood. 2016;128:2377.
- Chen CC, Parikh K, Abouzaid S, et al. Real-world treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or carfilzomib. J Manag Care Spec Pharm. 2017;23:236–246.
- Charlson ME, Charlson RE, Peterson JC, et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61:1234–1240.
- Wang HI, Smith A, Aas E, et al. Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort. Eur J Health Econ. 2017;18:255–267.
- Maurer MJ, Ghesquières H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32:1066–1073.
- Lee RC, Zou D, Demetrick DJ, et al. Costs associated with diffuse large B-cell lymphoma patient treatment in a Canadian integrated cancer care center. Value Health. 2008;11:221–230.
- Force RW, Pugmire BA, Culbertson VL. Comparing medical cost of care for patients with metastatic breast cancer receiving taxane therapy: claims analysis. Am Health Drug Benefits. 2010;3:276–284.
- Fitch K, Engel T, Sander S, et al. Cardiovascular event incidence and cost in type 2 diabetes mellitus: a Medicare claims-based actuarial analysis. Curr Med Res Opin. 2017;33:1795–1801.